US Patent

US12582620 — Oral solutions comprising lisdexamfetamine salts

Formulation · Assigned to Adalvo Ltd · Expires 2040-04-16 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an oral pharmaceutical solution formulation of lisdexamfetamine salts with a specific pH range and stability characteristics.

USPTO Abstract

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Drugs covered by this patent

Patent Metadata

Patent number
US12582620
Jurisdiction
US
Classification
Formulation
Expires
2040-04-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Adalvo Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.